Given the high Pol I transcriptional activity in cancers and the frequency at which transcriptional obstacles are encountered, it is likely that this creates significant pressure particularly in cancers to inactivate p53 by mutation to avoid launching of its tumor suppressive activities. The gene discussed is TP53; the disease is cancer.